Boundless Bio, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 2.47 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 56.18M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Details
| Name | Boundless Bio, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 28 |
| Founded | 2018 |
| Ipo Date | 2024-03-28 |
| Ceo | Jessica Oien |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 16.00 |
| Isin | US10170A1007 |
| Cusip | 10170A100 |
| Cik | 1782303 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Jessica Oien J.D. | President, Principal Executive Officer, Chief Legal Officer and Corporate Secretary |
| David Hinkle | Senior Vice President of Finance, Controller and Corporate Treasurer |
| Meredith Wesley | Chief Human Resources Officer |
Contact
| Address | 10955 Alexandria Way, Suite 100, San Diego, California 92121, United States |
| Phone | 858 766 9912 |
| Website | https://boundlessbio.com |